grant

Efficacy of buprenorphine and XR-naltrexone combination for relapse prevention in opioid use disorder

Organization NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INCLocation NEW YORK, UNITED STATESPosted 1 Aug 2020Deadline 30 Apr 2028
NIHUS FederalResearch GrantFY2026AbstinenceAdanonAddressAdherenceAdverse effectsAffectAgonistAlthoseAmbienAnxietyBehavioralBuprenorphineClinical TrialsClonazepamClonidineCombined Modality TherapyDevelopmentDolophineDoseDouble-Blind MethodDouble-Blind StudyDouble-BlindedDouble-Masked MethodDouble-Masked StudyDropoutDropsDrug Metabolic DetoxicationDrug Metabolic DetoxificationDrugsEarly treatmentEffectivenessEmotional DepressionEpidemicGoalsIndividualInjectionsInsomniaInsomnia DisorderKlofenilMaintenanceMeasuresMedicationMetabolic Drug DetoxicationsMetabolism of Toxic AgentsMethadoneMethadoseMethodsMonitorMoodsMorbidityMultimodal TherapyMultimodal TreatmentNalorexNaltrexoneNemexinOpiate AddictionOpiate AntagonistOpiate DependenceOpiate agonistOpiate receptor agonistOpiate receptor antagonistOpiatesOpioidOpioid AntagonistOpioid agonistOpioid receptor agonistOpioid receptor antagonistOralOutcomeOutcome MeasureParticipantPatientsPharmaceutical PreparationsPlacebo ControlPlacebosPopulationPreparationPrevention therapyRandomizedReViaRecoveryRelapseSafetySecureSeveritiesSham TreatmentSleep disturbancesSleeplessnessSymptomsTestingTimeTreatment outcomeVivitrolWithdrawalWithdrawal Symptomaberrant sleepaffective disturbanceantagonismantagonistanxiety symptomsanxious symptomarmclinical relevanceclinically relevantcombination therapycombined modality treatmentcombined treatmentcravingdepression symptomdepressivedepressive symptomsdetoxificationdevelopmentaldisrupted sleepdisturbance in affectdisturbed sleepdrug/agentdysphoriaearly therapyeffectiveness testingexperiencehigh riskillicit opiateillicit opioidimpaired sleepimprovedinterestirregular sleepmeasurable outcomemedication-assisted therapymedication-assisted treatmentmood alterationmood and affect disturbancemood disturbancemood dysfunctionmu opioid receptorsmulti-modal therapymulti-modal treatmentnew approachesnovel approachesnovel strategiesnovel strategyopiate abuseopiate consumptionopiate drug abuseopiate drug useopiate intakeopiate overdoseopiate related overdoseopiate useopiate use disorderopiate withdrawalopioid abuseopioid addictionopioid consumptionopioid dependenceopioid dependentopioid detoxopioid detoxificationopioid drug abuseopioid drug overdoseopioid drug useopioid induced overdoseopioid intakeopioid intoxicationopioid medication overdoseopioid overdoseopioid poisoningopioid related overdoseopioid toxicityopioid useopioid use disorderopioid withdrawaloutcome measurementoutpatient programsoutpatient servicesoverdose deathoverdose fatalitiespatient retentionpharmacologicpilot trialplacebo control trialplacebo controlledplacebo controlled trialprematureprematuritypreparationsprevent relapseprimary outcomeprotective effectrandomisationrandomizationrandomly assignedrecruitrelapse preventionrelapse risksham therapysleep disruptionsleep dysregulationsleep/wake disruptionsleep/wake disturbancezolpidemμ opioid receptorsμ-ORμOR
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Description preview

Opioid use disorder (OUD) reached epidemic proportions in the US with more than 2.5 million individuals
affected and dramatic increase in unintentional opioid-related overdose deaths. While maintenance with

buprenorphine is a leading treatment for opioid-dependent individuals, this is not acceptable to some patients,

nor is it universally…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →
Efficacy of buprenorphine and XR-naltrexone combination for relapse prevention in opioid use disorder — NEW YORK STATE P | Dev Procure